- Home
- MNPR vs ACRS Comparison
MNPR vs ACRS Comparison
Compare MNPR & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- ACRS
- Stock Information
- Founded
- MNPR 2014
- ACRS 2012
- Country
- MNPR United States
- ACRS United States
- Employees
- MNPR N/A
- ACRS N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- ACRS Health Care
- Exchange
- MNPR Nasdaq
- ACRS Nasdaq
- Market Cap
- MNPR 113.5M
- ACRS 132.0M
- IPO Year
- MNPR 2019
- ACRS 2015
- Fundamental
- Price
- MNPR $28.54
- ACRS $2.57
- Analyst Decision
- MNPR Strong Buy
- ACRS Strong Buy
- Analyst Count
- MNPR 4
- ACRS 5
- Target Price
- MNPR $38.50
- ACRS $11.00
- AVG Volume (30 Days)
- MNPR 59.4K
- ACRS 1.0M
- Earning Date
- MNPR 11-08-2024
- ACRS 02-25-2025
- Dividend Yield
- MNPR N/A
- ACRS N/A
- EPS Growth
- MNPR N/A
- ACRS N/A
- EPS
- MNPR N/A
- ACRS N/A
- Revenue
- MNPR N/A
- ACRS $27,079,000.00
- Revenue This Year
- MNPR N/A
- ACRS N/A
- Revenue Next Year
- MNPR N/A
- ACRS N/A
- P/E Ratio
- MNPR N/A
- ACRS N/A
- Revenue Growth
- MNPR N/A
- ACRS 26.35
- 52 Week Low
- MNPR $1.55
- ACRS $0.95
- 52 Week High
- MNPR $38.50
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- MNPR 60.16
- ACRS 43.12
- Support Level
- MNPR $24.00
- ACRS $2.31
- Resistance Level
- MNPR $26.52
- ACRS $2.57
- Average True Range (ATR)
- MNPR 2.42
- ACRS 0.18
- MACD
- MNPR 0.32
- ACRS 0.00
- Stochastic Oscillator
- MNPR 68.85
- ACRS 39.45
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.